

presentation to the animal's immune system of an immunologically effective amount of

- at least one GDF-8 polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the GDF-8 polypeptide or subsequence thereof induces production of antibodies against the GDF-8 polypeptide, or
- at least one GDF-8 analogue wherein the analogue has been modified so that at least one foreign T<sub>H</sub> epitope moiety (A) is introduced such that immunization of the animal with the analogue induces production of antibodies against the GDF-8 polypeptide.

C1  
Concl

Please add the following new claims:

54. (New) The method according to claim 1, wherein the GDF-8 polypeptide, the subsequence thereof, or the modified GDF-8 polypeptide optionally has been formulated with a pharmaceutically and immunologically acceptable carrier and/or vehicle and has been formulated with an adjuvant which facilitates breaking of autotolerance to autoantigens wherein said adjuvant is an aluminum adjuvant.

C2

55. (New) The method according to claim 1, wherein the natural T-cell epitope is a tetanus toxoid epitope.

56. (New) The method according to claim 1, wherein the GDF-8 subsequence or the GDF-8 analogue is derived from the C-terminal, active form of bovine GDF-8 polypeptide.